Zhaozhe Liu

General Hospital of Shenyang Military Region, Shenyang, Liaoning, China

Are you Zhaozhe Liu?

Claim your profile

Publications (6)3.98 Total impact

  • Article: Small breast epithelial mucin tumor tissue expression is associated with increased risk of recurrence and death in triple-negative breast cancer patients.
    [show abstract] [hide abstract]
    ABSTRACT: BACKGROUND: Small breast epithelial mucin (SBEM) has been implicated in tumor genesis and micrometastasis in breast cancer. Triple-negative breast cancer (TNBC) was characterized by high incidence in young women,early relapse and a very poor prognosis. The aim of this study was to evaluate the association of SBEM expression in tissues of TNBC with diseasefree survival (DFS) and overall survival (OS). METHODS: SBEM protein expression was detected in 87 available formalin-fixed paraffin-embedded (FFPE) tissue specimens from TNBC patients by means of immunohistochemistry (IHC). We analyzed the correlation between the SBEM protein expression and DFS and OS during a 5 year follow-up period, respectively. And a SBEM cut-off value of prognosis was established associated with DFS and OS. SBEM was analyzed against other risk factors in multivariate analysis. RESULTS: SBEM 3+ score was cut-off value of prognosis and significantly correlated with DFS (p = 0.000) and OS (p = 0.001) in TNBC patients. There was a marked associations (p <0.05) between SBEM 3+ score and tumor size, grade, node status, TNM stage and Ki67. Multivariate analysis showed that patients with SBEM 3+ represented a higher risk of recurrence and mortality than those with a lower SBEM expression (HR = 3.370 with p = 0.008 for DFS and HR = 4.185 with p = 0.004 for OS). CONCLUSIONS: SBEM is an independent risk predictor and may offer utility as a prognostic marker in TNBC patients. Virtual Slides http://www.diagnosticpathology.diagnomx.eu/vs/1624613061936917.
    Diagnostic Pathology 05/2013; 8(1):71. · 1.64 Impact Factor
  • Article: EGF +61A>G polymorphism and gastrointestinal cancer risk: A HuGE review and meta-analysis.
    [show abstract] [hide abstract]
    ABSTRACT: Emerging evidences from preclinical and clinical studies have shown that epidermal growth factor (EGF) has some effectiveness against endogenously arising carcinogenesis. Functional +61A>G polymorphism (rs4444903 A>G) in the promoter region of the EGF gene was observed to modulate EGF levels, thus affecting the susceptibility to gastrointestinal cancer; but individually published studies showed inconclusive results. The aim of this Human Genome Epidemiology (HuGE) review and meta-analysis was to derive a more precise estimation of the association between EGF +61A>G polymorphism and gastrointestinal cancer risk. A literature search of Pubmed, Embase, Web of Science and Chinese BioMedical databases from inception through July 2012 was conducted. Twelve studies were assessed with a total of 2868 gastrointestinal cancer cases and 4278 healthy controls. When all the eligible studies were pooled into the meta-analysis, the results showed that the G allele and GG genotype of EGF +61A>G polymorphism might increase the risk of gastrointestinal cancer. In the stratified analysis by cancer types, the G allele and GG genotype of EGF +61A>G polymorphism showed displayed significant correlations with increased risk of esophageal cancer. We also found significant correlations between the G carrier (GG+AG) and GG genotype of EGF +61A>G polymorphism and colorectal cancer risk. However, EGF +61A>G polymorphism did not appear to have an influence on gastric cancer susceptibility. Results from the current meta-analysis indicate that EGF +61A>G polymorphism might increase the risk of esophageal and colorectal cancers. Nevertheless, further studies are needed to determine whether genetic associations between EGF +61A>G polymorphism and susceptibility to gastric cancer are significant.
    Gene 02/2013; · 2.34 Impact Factor
  • Article: 169 patients with postoperative breast cancer on exercising the function of limbs and investigating quality of life: a clinical study
    [show abstract] [hide abstract]
    ABSTRACT: ObjectiveThe aim of this study was to observe the physical training influence on the limbs of postoperative breast cancer patients with adjuvant chemotherapy and do dual-response quality of life (QOL) according to clinical characteristics of patients. Methodsfrom February 2007 to December 2008, 169 patients with postoperative breast cancer were included. We put all the patients into two groups randomly, including 80 patients in the treatment group and 89 patients in the control group. When the cycle of chemotherapy has been completed or on the 28th day postoperatively, all the patients need to be measured the function of upper limbs. The patients in the treatment group perform the rehabilitative training by our rehabilitation gymnastics, and the patients in the control group perform the rehabilitative training by themselves. When 6 cycles of adjuvant chemotherapy have been completed, we evaluated the differences of the function of upper limbs in patients. At the same time, we hand out the QOL questionnaire to patients and their doctors for doing the two-way assessment. ResultsCompared with patients in control group, patients in treatment group have better in the abductive angle of shoulders and myodynamia (P = 0.000). By analysis on 156 (92.3%) questionnaires, we found that the match rate of doctors and patients with physiological functions and physical symptoms were better than mentation and relationships. The better match rate between doctors and patients in QOL questionnaires suggested that the QOL of patients would be improved in the higher rate. ConclusionExercising the function of limbs in early could be beneficial to the patients with postoperative breast cancer and effectively improve patient’s QOL. Meanwhile, we put doctors’ questionnaires in the assessment of patients’ QOL, and the results show that the assessment of patients’ QOL is more objective and complete. Key wordsbreast cancer-rehabilitation therapy-quality of life (QOL) questionnaire
    The Chinese-German Journal of Clinical Oncology 04/2012; 9(10):590-593.
  • Article: Primary application of a real-time quantitative polymerase chain reaction for the detection of human breast cancer related novel gene — Metadherin expression
    [show abstract] [hide abstract]
    ABSTRACT: ObjectiveThe aim of this study was to detect the expression level of Metadherin (MTDH) in peripheral blood of the breast cancer patients by real-time fluorescence quantitative polymerase chain reaction (PCR), and to explore the relationship between expression of Metadherin gene in the patients peripheral blood and the clinic-pathological features in breast cancer. MethodsReal-time fluorescence quantitative polymerase chain reaction was employed to determine the expression level of Metadherin gene in 80 peripheral blood samples of breast cancer patients and healthy donors. ResultsThe expression of Metadherin gene in breast cancer patients peripheral blood were positive, in which 34 breast cancer patients were highly expressed, accounting for 55.7%, while the expression of Metadherin gene in normal females peripheral blood were negative, there was statistical significance (Ratio = 2.02 ± 0.81, P < 0.05); Ratio of the Metadherin expression in breast cancer patients peripheral blood and the glyceraldehyde-3-phosphate dehydrogenase expression was 1.15 ± 0.36. REST software analysis showed that the expression of Metadherin gene was significantly up-regulated in breast cancer. ConclusionThe SYBR Green I quantitative real-time polymerase chain reaction method can successfully detect the expression level of Metadherin gene. Expression level of Metadherin gene in breast cancer patients peripheral blood is closely related to survival, and it maybe involved in the development of breast cancer and used as an indicator of prognosis. Key wordsbreast cancer-Metadherin (MTDH)-real-time fluorescence quantitative polymerase chain reaction (PCR)
    The Chinese-German Journal of Clinical Oncology 04/2012; 9(6):316-320.
  • Article: Research progress in triple-negative breast cancer
    Hongbo Lu, Xiaodong Xie, Zhaozhe Liu
    [show abstract] [hide abstract]
    ABSTRACT: Triple-negative breast cancer (TNBC) is a unique subgroup defined by a lack expression of ER (estrogen receptor), PR(progesterone receptor) and HER2 (human epidermal growth factor receptor 2), which has distinctly biological, clinical and pathological characteristics. This subgroup has close relationship with basal-like and BRCA1 (breast cancer susceptibility gene-1) breast cancers. Since endocrine and HER2-targered therapy can not be applied, chemotherapy is the major mean of therapy. Some studies show that TNBC is sensitive to taxol, platinum and anthracycline-based chemotherapy. Furthermore, targeted therapy to EGFR (epidermal growth factor receptor), c-kit (stem cell factor receptor) and PARP (poly ADP-ribose polymerase) inhibitor may show better anticancer activity. We will review this subgroup of breast cancer as the following three aspects, biological characteristics, clinicopathology characteristics and therapy strategy. Key wordsbreast cancer-triple-negative-BRCA1-targeted therapy-chemotherapy
    The Chinese-German Journal of Clinical Oncology 04/2012; 9(4):239-242.
  • Article: The application of Meta-analysis in the latest comprehensive treatment of breast cancer
    Fang Guo, Xiaodong Xie, Zhaozhe Liu
    [show abstract] [hide abstract]
    ABSTRACT: Meta-analysis is a kind of systematic review, which uses quantitative method to summarize the results. It is a comprehensive evaluation to the findings of previous studies with higher credibility. Recently, it is applied to all areas of scientific research, particularly in the integrated treatment of breast cancer. Currently, breast cancer is known one of the most common malignant tumors, and its incidence is increasing year by year. Therefore, more and more clinical doctors pay attention to the effect of comprehensive treatment for patients with breast cancer. This article mainly collects the results of comprehensive treatment of breast cancer, in which the method of Meta-analysis is applied. In addition, we discuss the latest progress in order to guide the clinical treatment.
    The Chinese-German Journal of Clinical Oncology 04/2012; 8(12):729-733.

Institutions

  • 2012
    • General Hospital of Shenyang Military Region
      Shenyang, Liaoning, China
    • Liaoning Universtity of Traditional Chinese Medicine
      Shenyang, Liaoning, China